Investment
Features
FeesSafety
Academy
More
Pluang+

Johnson & Johnson beats Q2 earnings estimates and raises 2026 sales and EPS guidance.

Company Fundamentals
15 Jul 2026
Proactive Investors
View Source
Bullish
Johnson & Johnson beats Q2 earnings estimates and raises 2026 sales and EPS guidance.

Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable sales from Tremfya and Darzalex offsetting patent losses on older drugs. The company raised its full-year 2026 guidance to $100.8-$101.4 billion in sales and adjusted EPS of $11.60-$11.75. CEO Joaquin Duato highlighted recent product approvals and a strong innovation pipeline, signaling confidence in reaching over $100 billion in annual revenue for the first time in its history.

More News (JNJ)

Low side effects and improved treatment experience reported for RYBREVANT FASPRO plus LAZCLUZE in advanced lung cancer

Low side effects and improved treatment experience reported for RYBREVANT FASPRO plus LAZCLUZE in advanced lung cancer

Johnson & Johnson announced positive Phase 2b COPERNICUS study results showing low rates of rash, blood clots, and administration-related reactions with subcutaneous RYBREVANT FASPRO plus LAZCLUZE in treating advanced non-small cell lung cancer with ...

Market News
Bullish
4 hours ago
RYBREVANT plus chemotherapy extends survival in advanced lung cancer with EGFR exon 20 mutations

RYBREVANT plus chemotherapy extends survival in advanced lung cancer with EGFR exon 20 mutations

Johnson & Johnson announced that RYBREVANT combined with chemotherapy significantly improved overall survival in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The Phase 3 PAPILLON study showed a...

Market News
Bullish
1 day ago
Five Dividend Kings offer steady, reliable income for retirees seeking low-risk investments.

Five Dividend Kings offer steady, reliable income for retirees seeking low-risk investments.

Five Dividend Kings—Procter & Gamble, Johnson & Johnson, Lowe’s, Emerson Electric, and Genuine Parts Company—are highlighted as top income stocks for retirees due to their decades-long records of annual dividend increases. These companies have mainta...

Market News
Bullish
2 days ago
iShares U.S. Pharmaceuticals ETF offers growth but faces risks from concentration and regulation, rated HOLD.

iShares U.S. Pharmaceuticals ETF offers growth but faces risks from concentration and regulation, rated HOLD.

The iShares U.S. Pharmaceuticals ETF (IHE) provides focused exposure to the US pharmaceutical sector, heavily weighted towards Johnson & Johnson and Eli Lilly. It benefits from growth drivers like obesity therapies and strong drug pipelines but carri...

Market News
Neutral
3 days ago
These 5 dividend stocks raised payouts through every recession since 1963, proving durable income potential.

These 5 dividend stocks raised payouts through every recession since 1963, proving durable income potential.

Five dividend stocks—Procter & Gamble, Johnson & Johnson, Coca-Cola, Colgate-Palmolive, and PepsiCo—have consistently raised their dividends through every U.S. recession since at least 1963. These companies demonstrated resilience during major downtu...

Market News
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App